当前位置:首页>产品中心>单抗/多抗>Anti-Human IL-17A/F Heterodimer Reference Antibody|抗人IL-17A/F异源二聚体参考抗体(靶标:人白细胞介素-17A/F异源二聚体)

Anti-Human IL-17A/F Heterodimer Reference Antibody|抗人IL-17A/F异源二聚体参考抗体(靶标:人白细胞介素-17A/F异源二聚体)

  • 货号:RB9THS856076
  • 价格:面议
  • 点击:181
   一键复制产品信息 复制成功!

产品介绍

产品参数

形态Liquid
宿主种属Human
克隆性Monoclonal
抗体亚型IgG1-kappa
纯度>95% as determined by SDS-PAGE.
纯化方式Protein A/G purified from cell culture supernatant.
浓度1 mg/ml
内毒素水平Please contact with the lab for this information.
应用ELISA, Bioactivity: FACS, Functional assay, Research in vivo
种属反应性Human
靶标CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A, IL17F, Interleukin-17F, IL-17F, Cytokine ML-1
储存缓冲液0.01M PBS, pH 7.4.
稳定性和储存Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
表达系统Mammalian Cells
登录号Q16552 & Q96PD4
背景信息Afasevikumab, also known as RG7624, is a human antibody inhibitor for human interleukin 17A (IL17A) and interleukin 17F (IL17F). This drug was developed by Genentech and has been investigated in the study of the treatment of inflammation diseases like autoimmune disorders. In 2013, Genentech completed a phase Ib study for the treatment of autoimmune disorders in Canada. However, it had been discontinued in 2015. In 2016, researchers used afasevikumab to conduct a phase I clinical trials for the treatment of inflammation in USA with no specified.
• IL-17 and IL-17-producing cells in protection versus pathology., PMID:35790881
• The IL-17 Family of Cytokines in Health and Disease., PMID:30995505
• The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond., PMID:30127781
• Functional specialization of interleukin-17 family members., PMID:21349428
• Serum Amyloid A Proteins Induce Pathogenic Th17 Cells and Promote Inflammatory Disease., PMID:31866067
• The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases., PMID:37600764
• The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis., PMID:30109481
• Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies., PMID:37373452
• Rhythmic IL-17 production by γδ T cells maintains adipose de novo lipogenesis., PMID:39478228
• Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation., PMID:29275332
别名MCAF-5352A, MCAF5352A, NI-1401, RG-7624, RG7624, RO5553110, 1589503-30-9
种属Human
备注For research use only. Not suitable for clinical or therapeutic use.
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Evolocumab Non-Neutralizing Recombinant Antibody |抗依洛尤单抗非中和重组抗体(靶标:依洛尤单抗非中和抗体) 537
Anti-Evolocumab Non-Neutralizing Recombinant Antibody |抗依洛尤单抗非中和重组抗体(靶标:依洛尤单抗非中和抗体) 526
Anti-Evolocumab Non-Neutralizing Recombinant Antibody |抗依洛尤单抗非中和重组抗体(靶标:依洛尤单抗非中和抗体) 449
Anti-Trastuzumab Neutralizing Recombinant Antibody |抗曲妥珠单抗中和重组抗体(靶标:曲妥珠单抗中和抗体) 593
Anti-Trastuzumab Neutralizing Recombinant Antibody |抗曲妥珠单抗中和重组抗体(靶标:曲妥珠单抗中和抗体) 660
Anti-Trastuzumab Neutralizing Recombinant Antibody |抗曲妥珠单抗中和重组抗体(靶标:曲妥珠单抗中和抗体) 657
Anti-Burosumab Neutralizing Recombinant Antibody |抗布罗索尤单抗中和重组抗体(靶标:布罗索尤单抗中和抗体) 368
Anti-Burosumab Neutralizing Recombinant Antibody |抗布罗索尤单抗中和重组抗体(靶标:布罗索尤单抗中和抗体) 408
Anti-Burosumab Non-Neutralizing Recombinant Antibody|抗布罗索尤单抗非中和重组抗体(靶标:布罗索尤单抗非中和抗体) 484
Anti-Rituximab Non-Neutralizing Recombinant Antibody |抗利妥昔单抗非中和重组抗体(靶标:利妥昔单抗非中和抗体) 521
Anti-Rituximab Non-Neutralizing Recombinant Antibody |抗利妥昔单抗非中和重组抗体(靶标:利妥昔单抗非中和抗体) 467
Anti-Rituximab Neutralizing Recombinant Antibody |抗利妥昔单抗中和重组抗体(靶标:利妥昔单抗中和抗体) 647
Anti-Rituximab Neutralizing Recombinant Antibody |抗利妥昔单抗中和重组抗体(靶标:利妥昔单抗中和抗体) 573
Anti-Zolbetuximab Non-Neutralizing Recombinant Antibody |抗佐贝妥昔单抗非中和重组抗体(靶标:佐贝妥昔单抗非中和抗体) 588
Anti-Zolbetuximab Non-Neutralizing Recombinant Antibody |抗佐贝妥昔单抗非中和重组抗体(靶标:佐贝妥昔单抗非中和抗体) 586
Anti-Zolbetuximab Non-Neutralizing Recombinant Antibody |抗佐贝妥昔单抗非中和重组抗体(靶标:佐贝妥昔单抗非中和抗体) 571
Anti-Zolbetuximab Neutralizing Recombinant Antibody |抗佐贝妥昔单抗中和重组抗体(靶标:佐贝妥昔单抗中和抗体) 343
Anti-Zolbetuximab Neutralizing Recombinant Antibody |抗佐贝妥昔单抗中和重组抗体(靶标:佐贝妥昔单抗中和抗体) 444
Anti-Zolbetuximab Neutralizing Recombinant Antibody |抗佐贝妥昔单抗中和重组抗体(靶标:佐贝妥昔单抗中和抗体) 426
Anti-Isatuximab Non-Neutralizing Recombinant Antibody |抗艾沙妥昔单抗非中和重组抗体(靶标:艾沙妥昔单抗非中和抗体) 325
总计 33037 个记录,共 1652 页,当前第 1644 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(微信
  • 我要留言
  • 周一至周五每天9:00-17:00